

## Table of content

<b>List of Figures</b> .....	ix
<b>List of Tables</b> .....	xiii
<b>Abbreviations</b> .....	xiv
<b>Preface</b> .....	xvi
<b>1.0 Introduction</b> .....	1-19
1.1 Causes of Cerebral Stroke .....	2
1.2 Epidemiology .....	2
1.3 Clinical diagnosis.. .....	3
1.4 Types of cerebral ischemia. ....	4
1.5 Animal models of focal cerebral ischemic stroke.....	7
1.6 Role of platelets in focal cerebral ischemic stroke. ....	8
1.7 Current guideline for the treatment of ischemic stroke.. .....	9
1.8 Possible treatment strategy for ischemic stroke.....	13
1.9 Origin of thesis.. .....	16
1.10 Hypothesis .....	16
1.11 Objectives of thesis ... .....	19
<b>2.0 Pharmacokinetic and Brain Penetration Study of Piracetam in Focal Cerebral Ischemic Rats</b> .....	20-42
2.1 Abstract... .....	20
2.2 Introduction.. .....	21
2.3 Hypothesis.. .....	24
2.4 Materials and methods.....	24
2.5 Results.. .....	31
2.6 Discussion.. .....	38
<b>3.0 Pharmacological effect of Barium Containing Bioactive Glass (BaBG) &amp; Silver Containing Bioactive Glass (AgBG) for the treatment of Cerebral Ischemic Reperfusion Injury</b> .....	43-86
3.1 Abstract... .....	43
3.2 Introduction.. .....	44
3.3 Hypothesis.. .....	46
3.4 Materials and methods.....	47
3.5 Results.. .....	58
3.6 Discussion.. .....	82
<b>4.0 Acute and Subacute Toxicity Studies of BaBG &amp; AgBG in Wistar Rats</b> .....	87-114
4.1 Abstract... .....	87
4.2 Introduction.. .....	88
4.3 Materials and methods.....	90
4.4 Results.. .....	94
4.5 Discussion.. .....	110

**5.0 Pharmacological effect of Barium Containing Bioactive Glass in Ischemic and other**

**Gastro-Duodenal Ulcers**..... 115-142

    5.1 Abstract..... 115

    5.2 Introduction..... 116

    5.3 Materials and methods..... 119

    5.4 Results..... 125

    5.5 Discussion..... 138

**6.0 Summary and Conclusion**..... 143-147

**References**..... 148-164

**List of publication from thesis**..... 165

## List of Figures

<b>Figure No.</b>	<b>Description</b>	<b>Page No.</b>
<b>Figure 1.1</b>	Proposed hypothesis	<b>18</b>
<b>Figure 2.1</b>	Proposed hypothesis	<b>24</b>
<b>Figure 2.2</b>	Chemical structure of piracetam	<b>25</b>
<b>Figure 2.3</b>	Schematic representation of the experimental design	<b>26</b>
<b>Figure 2.4</b>	Plasma log concentration-time curve of piracetam in control group rats and ischemic stroke group rats after oral administration of piracetam (200 mg/kg)	<b>32</b>
<b>Figure 2.5</b>	Plasma log concentration-time curve of piracetam in control group rats and ischemic group rats after intravenous administration of piracetam (75 mg/kg)	<b>32</b>
<b>Figure 2.6</b>	Represent the effects of piracetam on infarct volume in middle cerebral artery occlusion rats after 24 h post-dose	<b>37</b>
<b>Figure 3.1</b>	Proposed hypothesis	<b>47</b>
<b>Figure 3.2</b>	Schematic representation of the experimental design	<b>48</b>
<b>Figure 3.3</b>	FTIR transmittance spectral analysis of BaBG and 45S5 samples	<b>59</b>
<b>Figure 3.4</b>	(A) SEM images and (B) Energy-dispersive X-ray spectroscopy of BaBG	<b>60</b>
<b>Figure 3.5</b>	FTIR transmittance spectral analysis of AgBG and 45S5 samples	<b>61</b>
<b>Figure 3.6</b>	(A) SEM images and (B) Energy-dispersive X-ray spectroscopy of AgBG	<b>62</b>
<b>Figure 3.7</b>	(A) shows representative aggregation curve, (B) In-vitro dose-response inhibition curves of BaBG on ADP-induced platelet aggregation in healthy rat PRP	<b>63</b>
<b>Figure 3.8</b>	Ex-vivo effects of BaBG on ADP induced platelet aggregation in ischemic rat PRP	<b>64</b>
<b>Figure 3.9</b>	(A) shows representative aggregation curve, (B) In-vitro dose-response inhibition curves for AgBG inhibitory actions on ADP-induced platelet aggregation in healthy rat PRP	<b>65</b>
<b>Figure 3.10</b>	Ex-vivo effects of AgBG on ADP induced platelet aggregation in ischemic rat PRP	<b>66</b>
<b>Figure 3.11</b>	Bars represent the effect of BaBG on carrageenan induced tail thrombosis	<b>66</b>
<b>Figure 3.12</b>	Bars represent the effect of AgBG on carrageenan induced tail thrombosis	<b>67</b>
<b>Figure 3.13</b>	Bars represent the effect of BaBG on changes in mean CBF in MCAO rats	<b>68</b>
<b>Figure 3.14</b>	Bars represent the effect of AgBG on changes in mean CBF in MCAO rats	<b>69</b>
<b>Figure 3.15</b>	Bars represent the effect of BaBG on EEG changes in MCAO rats	<b>70</b>
<b>Figure 3.16</b>	Bars represent the effect of AgBG on EEG changes in MCAO rats	<b>71</b>
<b>Figure 3.17</b>	Effect of BaBG on brain infarct volume in MCAO rats	<b>72</b>

<b>Figure 3.18</b>	Effect of AgBG on brain infarct volume in MCAO rats	<b>73</b>
<b>Figure 3.19</b>	Bars represent the effect of BaBG on changes in behavioral test in MCAO rats	<b>75</b>
<b>Figure 3.20</b>	Bars represent the effect of AgBG on changes in behavioral test in MCAO rats	<b>76</b>
<b>Figure 3.21</b>	Effects of BaBG on cortex of the ischemic brain	<b>78</b>
<b>Figure 3.22</b>	(A) SEM images and (B) Energy-dispersive X-ray spectroscopy of cortex of the ischemic brain at the dose of 1.0 mg/kg BaBG on the last day of the experiment in MCAO rats	<b>78</b>
<b>Figure 3.23</b>	Effects of AgBG on cortex of the ischemic brain	<b>79</b>
<b>Figure 3.24</b>	(A) SEM images and (B) Energy-dispersive X-ray spectroscopy of cortex of the ischemic brain at the dose of 5.0 mg/kg AgBG on the last day of the experiment	<b>80</b>
<b>Figure 3.25</b>	Bars represent the effects of BaBG on VEGF level in MCAO rats	<b>80</b>
<b>Figure 3.26</b>	Bars represent the effects of AgBG on VEGF level in MCAO rats	<b>81</b>
<b>Figure 4.1</b>	Schematic representation of the experimental design	<b>91</b>
<b>Figure 4.2</b>	Effect of 28 days daily intravenous administration of BaBG at dose of 1, 10, and 50 mg/kg in histology stained with (H.E., haematoxylin and eosin) of highly perfused organ including kidney, liver, lung, spleen, stomach, brain, heart and bone marrow in rats	<b>106</b>
<b>Figure 4.3</b>	Effect of 28 days daily intravenous administration of AgBG at dose of 5, 10, and 50 mg/kg in histology stained with (H.E., haematoxylin and eosin) of highly perfused organ including kidney, liver, lung, spleen, stomach, brain, heart and bone marrow in rats	<b>108</b>
<b>Figure 4.4</b>	Deposition of BaBG in liver. Liver image A was captured at magnification of 200X shows presence of particle, while image B shows particle present on the liver specimen have barium and silica peaks that confirm the particles are of BaBG	<b>109</b>
<b>Figure 4.5</b>	Deposition of AgBG in liver. Liver image (A) was captured at magnification of 200X shows presence of particle, while image (B) shows particle present on the liver specimen have silver and silica peaks that confirm the particles are of AgBG	<b>109</b>
<b>Figure 5.1</b>	pH behavior after immersion of the BaBG and 45S5 samples in SBF. Data are expressed as means $\pm$ SEM (n=3). $p < 0.05$ and $p < 0.05$ compared with the 45S5 group on day 6 and 7 respectively	<b>126</b>
<b>Figure 5.2</b>	Bars represent the effect of BaBG on gastric blood flow	<b>127</b>
<b>Figure 5.3</b>	Bars represent the effect of BaBG on gross damage index in CAO rats	<b>127</b>
<b>Figure 5.4</b>	Bars represent the effect of BaBG on VEGF level on ischemic gastric mucosal tissue in CAO rats	<b>128</b>
<b>Figure 5.5</b>	Control group rats of ethanol-induced ulcer model have no disruption of the surface epithelium (A & G). Rats in the vehicle group have severe disruption of the	<b>129</b>

	<p>surface epithelium, and extensive oedema of the submucosal layer and leukocyte infiltration are present (B &amp; H). Rat in BaBG 0.3 mg/kg has disruption of the surface epithelium, and there is submucosal oedema (C &amp; I). BaBG 1.0 mg/kg rat has moderate disruption of the surface epithelium with oedema of the submucosal layer (D &amp; J). Rats in BaBG 3 mg/kg showed a mild disruption of the surface epithelium (E &amp; K). The gastric mucosa in animals pretreated with omeprazole showed a mild disruption of the surface epithelium (F &amp; L). Macroscopic damage indices were quantified (M)</p>	
<b>Figure 5.6</b>	<p>(A-D) shows the SEM images of gastric epithelial cells. (A) shows image of the sham group of the ethanol-induced model with normal gastric epithelial cell. (B) shows image of vehicle group and white arrow indicates severe damage in gastric epithelial cell. (C) shows image of treatment (1.0 mg/kg) group and white arrow indicate the formation of BaBG protective layer over the damaged gastric epithelial cell. Further image (D) clearly shown binding of BaBG at the erosive part of the stomach</p>	<b>130</b>
<b>Figure 5.7</b>	<p>Control group rats of pylorus ligation induced ulcer model have no disruption of the surface epithelium (A &amp; G). Rats in the vehicle group have severe disruption of the surface epithelium, and extensive oedema of the submucosal layer and leukocyte infiltration are present (B &amp; H). Rat in BaBG 0.3 mg/kg has disruption of the surface epithelium, and there is submucosal oedema (C &amp; I). BaBG 1.0 mg/kg rat has moderate disruption of the surface epithelium with oedema of the submucosal layer (D &amp; J). Rats in BaBG 3 mg/kg showed a mild disruption of the surface epithelium (E &amp; K). The gastric mucosa in animals pretreated with omeprazole showed a mild disruption of the surface epithelium (F &amp; L). Macroscopic damage indices were quantified (M)</p>	<b>132</b>
<b>Figure 5.8</b>	<p>Rats in the control group of aspirin-induced gastric ulcers model have no disruption of the surface epithelium (A). Rats in the vehicle group have severe disruption of the surface epithelium (B). Rat in BaBG 0.3 mg/kg has disruption of the surface epithelium (C). BaBG 1.0 mg/kg rat has moderate disruption of the surface epithelium (D). Rats in BaBG 3 mg/kg showed a mild disruption of the surface epithelium (E). The gastric mucosa in animals pretreated with omeprazole showed a mild disruption of the surface epithelium (F). Macroscopic damage indices were quantified (G)</p>	<b>134</b>
<b>Figure 5.9</b>	<p>Rats in the control group of acetic acid-induced chronic gastric ulcers model have no disruption of the surface epithelium (A). Rats in the vehicle group have severe disruption of the surface epithelium (B). Rat in BaBG 0.3 mg/kg has disruption of the surface</p>	<b>136</b>

	epithelium (C). BaBG 1.0 mg/kg rat has moderate disruption of the surface epithelium (D). Rats in BaBG 3 mg/kg showed a mild disruption of the surface epithelium (E). The gastric mucosa in animals pretreated with omeprazole showed a mild disruption of the surface epithelium (F). Macroscopic damage indices in rats were quantified (G)	
<b>Figure 5.10</b>	Bars represent the macroscopic damage indices in rats	<b>137</b>
<b>Figure 5.11</b>	SEM images (A-D) and EDS analysis (E) of the intestine of cysteamine-induced duodenal ulcer models at 3 mg/kg BaBG dose confirm the binding of BaBG onto the surface of the intestine. Duodenum images A, B, C and D were captured at a magnification of 200, 500, 1000 and 5000×. Lower magnification (A and B) shows microvilli of the intestine while the same images at higher magnification (C and D) show BaBG particle adsorbed at the surface of the microvilli. Image E shows particle adsorbed at the surface of the intestinal villi have barium and silica peaks that confirm the particles are of BaBG	<b>137</b>
<b>Figure 6.1</b>	Proven hypothesis. “-” denotes inhibition and “+” denotes activation	<b>147</b>

### List of Tables

<b>Table No.</b>	<b>Description</b>	<b>Page No.</b>
<b>Table 1.1</b>	Available treatment of ischemic stroke as per American Stroke Association and their shortcomings	<b>10</b>
<b>Table 1.2</b>	Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis	<b>13</b>
<b>Table 1.3</b>	Bioglass™ or 45S5 composition	<b>14</b>
<b>Table 2.1</b>	Pharmacokinetic parameters of piracetam in control and ischemic stroke rats	<b>33</b>
<b>Table 2.2</b>	Brain Penetration data of piracetam in control and ischemic stroke rats after oral administration at 200 mg/kg dose	<b>34</b>
<b>Table 2.3</b>	Exposure of Piracetam in control and ischemic stroke rats at 200 mg/kg oral and 75 mg/kg intravenous doses	<b>35</b>
<b>Table 4.1</b>	Effect of BaBG treatment on feed consumption, water consumption and changes in body weight	<b>95</b>
<b>Table 4.2</b>	Effect of AgBG treatment on feed consumption, water consumption and changes in body weight	<b>96</b>
<b>Table 4.3</b>	Effect of BaBG treatment on organ weight / body weight coefficients	<b>97</b>
<b>Table 4.4</b>	Effect of AgBG treatment on organ weight / body weight coefficients	<b>97</b>
<b>Table 4.5</b>	Effect of BaBG on ECG parameters and blood pressure	<b>98</b>
<b>Table 4.6</b>	Effect of AgBG on ECG parameters and blood pressure	<b>99</b>
<b>Table 4.7</b>	Effect of BaBG on hematological parameters	<b>100</b>
<b>Table 4.8</b>	Effect of AgBG on hematological parameters	<b>102</b>
<b>Table 4.9</b>	Effect of BaBG in surface blood flow of highly perfused organ	<b>104</b>
<b>Table 4.10</b>	Effect of AgBG in surface blood flow of highly perfused organ	<b>105</b>
<b>Table 5.1</b>	Effect of BaBG on cell proliferation of stomach in pylorus-ligated rats (data are mean $\pm$ S.E.M., n=6 in each group).	<b>131</b>
<b>Table 5.2</b>	Effect of BaBG on gastric pH in rats	<b>134</b>
<b>Table 5.3</b>	Effect of BaBG on gastric fluid volume in rats	<b>135</b>